Search Results - "Flandre, P."

Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing by Nguyen, T, Fofana, D B, Lê, M P, Charpentier, C, Peytavin, G, Wirden, M, Lambert-Niclot, S, Desire, N, Grude, M, Morand-Joubert, L, Flandre, P, Katlama, C, Descamps, D, Calvez, V, Todesco, E, Marcelin, A G

“…Integrase strand transfer inhibitors (INSTIs) are recommended by international guidelines as first-line therapy in antiretroviral-naive and -experienced…”
Get full text

HIV MDR is still a relevant issue despite its dramatic drop over the years by Armenia, D, Di Carlo, D, Flandre, P, Bouba, Y, Borghi, V, Forbici, F, Bertoli, A, Gori, C, Fabeni, L, Gennari, W, Pinnetti, C, Mondi, A, Cicalini, S, Gagliardini, R, Vergori, A, Bellagamba, R, Malagnino, V, Montella, F, Colafigli, M, Latini, A, Marocco, R, Licthner, M, Andreoni, M, Mussini, C, Ceccherini-Silberstein, F, Antinori, A, Perno, C F, Santoro, M M

“…Abstract Objectives To evaluate the prevalence and therapeutic relevance of drug resistance among isolates from ART-experienced HIV-1-infected patients over…”
Get full text

Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination by Lambert-Niclot, S, Allavena, C, Grude, M, Flandre, P, Sayon, S, Andre, E, Wirden, M, Rodallec, A, Jovelin, T, Katlama, C, Calvez, V, Raffi, F, Marcelin, A-G

“…In the context of a rilpivirine/emtricitabine/tenofovir disoproxil fumarate switch in HIV-1-infected patients with at least 1 year of virological success, we…”
Get full text

Comparison of 48‐week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor‐sparing regimens: a systematic review and network meta‐analysis by Gallien, S, Massetti, M, Flandre, P, Leleu, H, Descamps, D, Lazaro, E

“…Objectives To compare nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)‐sparing regimens with tenofovir alafenamide (TAF)‐based combinations in…”
Get full text

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses by Lambert-Niclot, S, Charpentier, C, Storto, A, Fofana, D B, Soulié, C, Fourati, S, Visseaux, B, Wirden, M, Morand-Joubert, L, Masquelier, B, Flandre, P, Calvez, V, Descamps, D, Marcelin, A-G

“…The prevalence of rilpivirine, emtricitabine and tenofovir resistance-associated mutations (RAMs), described in vitro and in vivo, was determined in…”
Get full text

Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study by Valantin, M. A., Lambert-Niclot, S., Flandre, P., Morand-Joubert, L., Cabiè, A., Meynard, J. L., Ponscarme, D., Ajana, F., Slama, L., Curjol, A., Cuzin, L., Schneider, L., Taburet, A. M., Marcelin, A. G., Katlama, C.

“…Objectives Long-term results at week 96 are needed to evaluate the capacity of the darunavir/ritonavir monotherapy strategy to maintain a sustained control of…”
Get full text

Increased risk of IRIS-associated tuberculosis in HIV-infected patients receiving Integrase Inhibitors by Gaillet, A., Calin, R., Flandre, P., Tubiana, R., Valantin, M.-A., Caumes, E., Katlama, C., Pourcher, V.

“…•ART-containing integrase inhibitors could be associated with higher incidence of TB-associated IRIS.•Prospective studies are needed to better characterize the…”
Get full text

Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy by Lambert-Niclot, S., Charpentier, C., Storto, A., Fofana, D., Soulie, C., Fourati, S., Wirden, M., Morand-Joubert, L., Masquelier, B., Flandre, P., Calvez, V., Descamps, D., Marcelin, A. G.

“…Objectives In the context of simplification strategies, it is essential to know the feasibility of a switch to a rilpivirine-based therapy. The aim of this…”
Get full text

Prospective one-year bone loss in treatment-naïve HIV+ men and women on single or multiple drug HIV therapies by Briot, K, Kolta, S, Flandre, P, Boué, F, Ngo Van, P, Cohen-Codar, I, Norton, M, Delfraissy, J.F, Roux, C

“…Abstract Antiretroviral therapy has decreased the rate of HIV-related mortality and extended the life span of HIV patients. Current guidelines recommend the…”
Get full text

Virological failure of patients on maraviroc-based antiretroviral therapy by Raymond, Stéphanie, Maillard, Anne, Amiel, Corinne, Peytavin, Gilles, Trabaud, Mary Anne, Desbois, Delphine, Bellecave, Pantxika, Delaugerre, Constance, Soulie, Cathia, Marcelin, Anne Geneviève, Descamps, Diane, Izopet, Jacques

“…Virological failure (VF) in patients on maraviroc-based treatment has been associated with altered HIV tropism and resistance to maraviroc. This multicentre…”
Get full text

Long‐term (96‐week) follow‐up of antiretroviral‐naïve HIV‐infected patients treated with first‐line lopinavir/ritonavir monotherapy in the MONARK trial by Ghosn, J, Flandre, P, Cohen‐Codar, I, Girard, P‐M, Chaix, M‐L, Raffi, F, Dellamonica, P, NgoVan, P, Norton, M, Delfraissy, J‐F

“…Background The toxicities, cost and complexity of triple combinations warrant the search for other treatment options, such as boosted protease inhibitor (PI)…”
Get full text

Efficacy of etravirine combined with darunavir or other ritonavir‐boosted protease inhibitors in HIV‐1‐infected patients: an observational study using pooled European cohort data by Vingerhoets, J, Calvez, V, Flandre, P, Marcelin, A‐G, Ceccherini‐Silberstein, F, Perno, C‐F, Mercedes Santoro, M, Bateson, R, Nelson, M, Cozzi‐Lepri, A, Grarup, J, Lundgren, J, Incardona, F, Kaiser, R, Sonnerborg, A, Clotet, B, Paredes, R, Günthard, HF, Ledergerber, B, Hoogstoel, A, Nijs, S, Tambuyzer, L, Lavreys, L, Opsomer, M

“…Objectives This observational study in antiretroviral treatment‐experienced, HIV‐1‐infected adults explored the efficacy of etravirine plus darunavir/ritonavir…”
Get full text

Body fat distribution in HIV‐infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI‐ANRS136 Substudy by Valantin, MA, Kolta, S, Flandre, P, Algarte Genin, M, Meynard, JL, Ponscarme, D, Slama, L, Cuzin, L, Kerviler, E, Inaoui, R, Katlama, C

“…Objectives The aim of the study was to evaluate fat tissue distribution in HIV‐infected patients with suppressed viraemia treated with darunavir/ritonavir…”
Get full text

Patients with HIV-1 RNA below 1000 copies/ml after 48 weeks on dual nucleoside combination therapy by FLANDRE, P

Get full text

Salivary Cytomegalovirus (CMV) Shedding, Glycoprotein B Genotype Distribution, and CMV Disease in Human Immunodeficiency Virus-Seropositive Patients by Fidouh-Houhou, N., Duval, X., Bissuel, F., Bourbonneux, V., Flandre, P., Ecobichon, J. L., Jordan, M. C., Vildé, J. L., Brun-Vézinet, F., Leport, C.

“…To assess the frequency of shedding of cytomegalovirus (CMV) in saliva, the distribution of CMV glycoprotein B (gB) genotypes, and the occurrence of CMV…”
Get full text

National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation by Delaugerre, C., Flandre, P., Marcelin, A.G., Descamps, D., Tamalet, C., Cottalorda, J., Schneider, V., Yerly, S., LeGoff, J., Morand-Joubert, L., Chaix, M.L., Costagliola, D., Calvez, V.

“…Tenofovir disoproxil fumarate (TDF) has become an important component of HIV combination therapy because of its potency and once‐daily dosing. Key mutation…”
Get full text

Analysing survival in the presence of an auxiliary variable by Flandre, P

Get full text

Estimating the proportion of treatment effect explained by a surrogate marker by Flandre, P, Saidi, Y

Get full text

Pattern and evolution of the prescription of olanzapine during one year: Results of the cohort study ECOL by Gasquet, I, Flandre, P, Heurtebize, N, Deal, C, Perrin, E, Chartier, F, Fourrier-Réglat, A

“…The necessary evidence of new therapies of clinical interest extends beyond clinical trials in a less controlled population and closer to clinical practice…”
Get more information

Cytomegalovirus (CMV) Viremia and the CD4+ Lymphocyte Count as Predictors of CMV Disease in Patients Infected with Human Immunodeficiency Virus by Gérard, L., Leport, C., Flandre, P., Houhou, N., Salmon-Céron, D., Pépin, J. M., Mandet, C., Brun-Vézinet, F., Vildé, J. L.

“…We screened 192 patients infected with human immunodeficiency virus (HIV) to examine the relation between CD4+ lymphocyte counts and cytomegalovirus (CMV)…”
Get full text